These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 575925)
1. Behavioural effects of drugs acting on the central dopaminergic neurons. Georgiev V; Markovska V Act Nerv Super (Praha); 1977 Jul; 19 Suppl 2():335-6. PubMed ID: 575925 [No Abstract] [Full Text] [Related]
2. Self-inhibitory dopamine-receptors and central effects of apomorphine. Di Chiara G; Porceddu ML; Morelli M; Gessa GL Ann Ist Super Sanita; 1978; 14(1):111-22. PubMed ID: 756166 [TBL] [Abstract][Full Text] [Related]
3. Dose-response shifts in the behavioural effects of dopamine agonists and antagonists following chronic morphine treatment. Overstreet DH; Smee ML; Woolston ME Proc West Pharmacol Soc; 1976; 19():248-53. PubMed ID: 1033554 [No Abstract] [Full Text] [Related]
4. Apomorphine and central serotonin neurons. Grabowska M; Antkiewicz L; Maj J; Michaluk J Pol J Pharmacol Pharm; 1973; 25(1):29-39. PubMed ID: 4272897 [No Abstract] [Full Text] [Related]
5. Studies on the participation of the dopaminergic system in the central effects of chelidonine. Kleinrok Z; Szponar J; Matuszek B; Jagiełło-Wójtowicz E Pol J Pharmacol Pharm; 1990; 42(5):417-24. PubMed ID: 2098751 [TBL] [Abstract][Full Text] [Related]
6. Some behavioural effects of chloroquine in rats suggesting dopaminergic activation. Amabeoku GJ Indian J Med Res; 1994 Feb; 99():87-94. PubMed ID: 8005645 [TBL] [Abstract][Full Text] [Related]
7. Activity of ibopamine on central nervous system in mice and rats. Ferrini R; Miragoli G; Sala R; Reggiani A Arzneimittelforschung; 1986 Feb; 36(2A):327-30. PubMed ID: 3707643 [TBL] [Abstract][Full Text] [Related]
8. Behavioral effects of apomorphine during development of rats. Brus R; Herman ZS; Jamrozik Z Acta Physiol Pol; 1977; 28(3):243-6. PubMed ID: 561515 [TBL] [Abstract][Full Text] [Related]
9. Differentiation of the central dopaminergic stimulants apomorphine and lergotrile. Wade RL; Krewsun I; Quock RM Proc West Pharmacol Soc; 1979; 22():141-2. PubMed ID: 42079 [No Abstract] [Full Text] [Related]
11. The locomotor and stereotype response to dopaminergic drugs and caffeine after intracerebroventricular kainic acid in rats. Kleinrok Z; Turski L; Wawrzyniak M; Cybulska R Pol J Pharmacol Pharm; 1981; 33(2):149-59. PubMed ID: 7198226 [TBL] [Abstract][Full Text] [Related]
12. Dopaminergic influence on the effects of angiotensin II in behavioural reactions. Georgiev V; György L; Yonkov D; Getova D; Markovska V; Petkova B Physiol Bohemoslov; 1985; 34 Suppl():45-8. PubMed ID: 3014581 [TBL] [Abstract][Full Text] [Related]
13. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity. De Veaugh-Geiss J; Devanand DP; Carey RJ Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268 [TBL] [Abstract][Full Text] [Related]
14. Effects of dopaminergic drugs on phencyclidine-induced behavior in the rat. Castellani S; Adams PM Neuropharmacology; 1981 Apr; 20(4):371-4. PubMed ID: 7197334 [No Abstract] [Full Text] [Related]
15. Modulation of dopamine receptor sensitivity by estrogen. Gordon JH; Borison RL; Diamond BI Biol Psychiatry; 1980 Jun; 15(3):389-96. PubMed ID: 7189674 [TBL] [Abstract][Full Text] [Related]
16. Scopolamine-induced hypermotility in rats is mediated via a dopaminergic system. Fink H; Morgenstern R Acta Biol Med Ger; 1980; 39(8-9):903-10. PubMed ID: 7282220 [TBL] [Abstract][Full Text] [Related]
17. The involvement of serotonin in the mechanism of central action of apomorphine. Grabowska M Pol J Pharmacol Pharm; 1976; 28(4):389-94. PubMed ID: 790347 [TBL] [Abstract][Full Text] [Related]
18. Multiple receptors for brain dopamine in behavior regulation: concept of dopamine-E and dopamine-I receptors. Cools AR; van Rossum JM Life Sci; 1980 Oct; 27(14):1237-53. PubMed ID: 6255271 [No Abstract] [Full Text] [Related]
19. Dopaminergic and cholinergic influences on motor behavior in chickens. Sanberg PR J Comp Psychol; 1983 Mar; 97(1):59-68. PubMed ID: 6872506 [TBL] [Abstract][Full Text] [Related]
20. The influence of antineoplaston A5 on the central dopaminergic structures. Juszkiewicz M; Chodkowska A; Burzynski SR; Feldo M; Majewska B; Kleinrok Z Drugs Exp Clin Res; 1994; 20(4):161-7. PubMed ID: 7813388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]